Loading…
Loading grant details…
| Funder | Vinnova |
|---|---|
| Recipient Organization | Key2Brain Ab |
| Country | Sweden |
| Start Date | May 22, 2023 |
| End Date | May 20, 2024 |
| Duration | 364 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | Swedish Research Council |
| Grant ID | 2023-00344_Vinnova |
Purpose and goal:
The goal of the project, to prepare our targeting technology for clinical phase together with collaborators, has been achieved in several ways. We have validated the functionality and strength of our technology and our competence, as well as protected intellectual property rights, which is a prerequisite for further work.
Expected results and effects:
As a result of the project, our technology has been validated to create future drug candidates. Our technology has proven to be versatile and suitable as part of new drugs with maintained function, as well as translationally adapted for humans. Our team has grown and we continue to expand both on a staff level and in partners and revenue.
Approach and implementation:
We have systematically worked our way through various work packages that have driven the project to completion. By tackling several issues in parallel, we have been able to accelerate our development towards clinical application. New methods have been established and new intellectual property rights have been built up.
Key2Brain Ab
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant